Allergen Testing and Immunotherapy: Current and Future Approaches
Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific ImmunotherapyVrtala S.a · Hirtenlehner K.a · Susani M.e · Hufnagl P.c · Binder B.R.c · Vangelista L.d · Pastore A.d · Sperr W.R.b · Valent P.b · Ebner C.a · Kraft D.a · Valenta R.a
aInstitute of General and Experimental Pathology, and bDepartment of Internal Medicine I, Division of Hematology, AKH, and cDepartment of Vascular Biology and Thrombosis Research, University of Vienna, Austria; dEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany; eABS, Institute of Molecular Biology, Salzburg, Austria
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
- Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Scheiner O, Kraft D: IgE and IgG antibodies of patients with allergy to birch as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44:385–395.
- Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H, Scheiner O, Breitenbach M: The gene coding for the major birch pollen allergen Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J 1989;8:1935–1938.
- Valenta R, Duchêne M, Vrtala S, Birkner T, Ebner C, Hirschwehr R, Breitenbach M, Rumpold H, Scheiner O, Kraft D: Recombinant allergens for immunoblot diagnosis of tree pollen allergy. J Allergy Clin Immunol 1991;88:889–894.
- Niederberger V, Pauli G, Grönlund H, Fröschl R, Rumpold H, Kraft D, Valenta R, Spitzauer S: Recombinant birch pollen allergens (rBet v 1, rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel and oak pollen: A quantitative IgE inhibition study using sera from different populations. J Allergy Clin Immunol 1998;102:579–591.
- Ebner C, Hirschwehr R, Bauer L, Breiteneder H, Valenta R, Ebner H, Kraft D, Scheiner O: Identification of allergens in fruits and vegetables: IgE crossreactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995;95:962–969.
- Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler H–G, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope–containing fragments. Candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673– 1681.
Pauli G, Purohit A, Oster JP, Vrtala S, Niederberger V, Kraft D, Valenta R: Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives. Int Arch Allergy Immunol 1999;in press.
- Valenta R, Almo S, Ball T, Dolecek C, Steinberger P, Laffer S, Eibensteiner P, Flicker S, Vrtala S, Spitzauer S, Valent P, Denepoux S, Kraft D, Banchereau J, Lebecque S: The immunoglobulin E–allergen interaction: A target for therapy of type I allergic diseases. Int Arch Allergy Immunol 1998;116:167–176.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.